Matches in SemOpenAlex for { <https://semopenalex.org/work/W2280859858> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2280859858 endingPage "3513" @default.
- W2280859858 startingPage "3513" @default.
- W2280859858 abstract "3513 Background: RAD001C exerts antiproliferative and antiangiogenic effects by mTOR (mammalian target of rapamycin) inhibition. mTOR is critical in the transduction of proliferative signals mediated via the PI3K/Akt pathway. This signal transduction pathway is relevant to HER2 and ER signaling, and in PTEN mutated tumors, thus mTOR may be a central and relevant factor in breast cancer. Methods: Multi-center randomized phase II study assessing two oral schedules of RAD001C: Arm A (A)_10 mg daily, or Arm B (B)_70 mg weekly, assessed clinically each 4 weeks, imaged each 8 weeks. Eligibility: Patients (pts) with measurable metastatic breast cancer (MBC) who may have received adjuvant chemotherapy (CT), with up to one prior CT for advanced/recurrent disease. Stratification factors: 0 or 1 prior CT for MBC; presence/absence of visceral metastases. Primary endpoint: clinical/radiologic response and early progression (<8 wks). Two-stage accrual design with 15 evaluable pts in each arm in first phase. If =1 response and <10 early PD, add 15 pts. Arm B was discontinued after stage 1 as no responses were seen. A higher than expected occurrence of pneumonitis (Pn) occurred in both arms, higher in arm A. Results: Median age was 60yrs, 32 pts had prior CT, 20 pts had liver metastases. The most common drug related toxicities were fatigue, rash, anorexia, diarrhea, stomatitis, cough and pneumonitis; pulmonary effects appeared schedule related. (See results table below) Conclusions: Daily oral RAD001C has activity in MBC. The final results of this randomized Phase II trial will provide data to plan future breast cancer trials of RAD001C. [Table: see text] [Table: see text]" @default.
- W2280859858 created "2016-06-24" @default.
- W2280859858 creator A5009137268 @default.
- W2280859858 creator A5015979970 @default.
- W2280859858 creator A5036689689 @default.
- W2280859858 creator A5040210551 @default.
- W2280859858 creator A5044291041 @default.
- W2280859858 creator A5067292894 @default.
- W2280859858 creator A5069819791 @default.
- W2280859858 creator A5087850212 @default.
- W2280859858 date "2007-06-20" @default.
- W2280859858 modified "2023-10-18" @default.
- W2280859858 title "A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer" @default.
- W2280859858 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.3513" @default.
- W2280859858 hasPublicationYear "2007" @default.
- W2280859858 type Work @default.
- W2280859858 sameAs 2280859858 @default.
- W2280859858 citedByCount "9" @default.
- W2280859858 crossrefType "journal-article" @default.
- W2280859858 hasAuthorship W2280859858A5009137268 @default.
- W2280859858 hasAuthorship W2280859858A5015979970 @default.
- W2280859858 hasAuthorship W2280859858A5036689689 @default.
- W2280859858 hasAuthorship W2280859858A5040210551 @default.
- W2280859858 hasAuthorship W2280859858A5044291041 @default.
- W2280859858 hasAuthorship W2280859858A5067292894 @default.
- W2280859858 hasAuthorship W2280859858A5069819791 @default.
- W2280859858 hasAuthorship W2280859858A5087850212 @default.
- W2280859858 hasConcept C121608353 @default.
- W2280859858 hasConcept C126322002 @default.
- W2280859858 hasConcept C143998085 @default.
- W2280859858 hasConcept C203092338 @default.
- W2280859858 hasConcept C2775930923 @default.
- W2280859858 hasConcept C2777714996 @default.
- W2280859858 hasConcept C2778570526 @default.
- W2280859858 hasConcept C2779524853 @default.
- W2280859858 hasConcept C31760486 @default.
- W2280859858 hasConcept C530470458 @default.
- W2280859858 hasConcept C535046627 @default.
- W2280859858 hasConcept C71924100 @default.
- W2280859858 hasConcept C90924648 @default.
- W2280859858 hasConceptScore W2280859858C121608353 @default.
- W2280859858 hasConceptScore W2280859858C126322002 @default.
- W2280859858 hasConceptScore W2280859858C143998085 @default.
- W2280859858 hasConceptScore W2280859858C203092338 @default.
- W2280859858 hasConceptScore W2280859858C2775930923 @default.
- W2280859858 hasConceptScore W2280859858C2777714996 @default.
- W2280859858 hasConceptScore W2280859858C2778570526 @default.
- W2280859858 hasConceptScore W2280859858C2779524853 @default.
- W2280859858 hasConceptScore W2280859858C31760486 @default.
- W2280859858 hasConceptScore W2280859858C530470458 @default.
- W2280859858 hasConceptScore W2280859858C535046627 @default.
- W2280859858 hasConceptScore W2280859858C71924100 @default.
- W2280859858 hasConceptScore W2280859858C90924648 @default.
- W2280859858 hasIssue "18_suppl" @default.
- W2280859858 hasLocation W22808598581 @default.
- W2280859858 hasOpenAccess W2280859858 @default.
- W2280859858 hasPrimaryLocation W22808598581 @default.
- W2280859858 hasRelatedWork W1968731610 @default.
- W2280859858 hasRelatedWork W1981180604 @default.
- W2280859858 hasRelatedWork W2009096079 @default.
- W2280859858 hasRelatedWork W2114699723 @default.
- W2280859858 hasRelatedWork W2115964437 @default.
- W2280859858 hasRelatedWork W2163467469 @default.
- W2280859858 hasRelatedWork W2329107753 @default.
- W2280859858 hasRelatedWork W2995532498 @default.
- W2280859858 hasRelatedWork W3125059937 @default.
- W2280859858 hasRelatedWork W4284988128 @default.
- W2280859858 hasVolume "25" @default.
- W2280859858 isParatext "false" @default.
- W2280859858 isRetracted "false" @default.
- W2280859858 magId "2280859858" @default.
- W2280859858 workType "article" @default.